Navigation Links
Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes
Date:11/21/2010

STANFORD, Calif. Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

"Studies of this type, which used to take months in animal models, can now occur on a time scale of days," said Paul Khavari, MD, PhD, the Carl J. Herzog Professor and chair of dermatology at Stanford. The researchers focused on epithelial cells, which line the surfaces and cavities of the body. Cancers of epithelial cells make up approximately 90 percent of all human cancers.

The study of three-dimensional tumors also avoids the use of cancer cell lines, which are typically grown in single layers and may have accumulated genetic changes that don't accurately reflect what happens in humans.

Khavari, who is also a member of the Stanford Cancer Center and serves as dermatology service chief at the Veterans Affairs Palo Alto Health Care System, is the senior author of the research, which will be published online Nov. 21 in Nature Medicine. Todd Ridky, MD, PhD, a former postdoctoral scholar in Khavari's laboratory, is the first author. Ridky is now an assistant professor at the University of Pennsylvania.

The researchers worked with normal human epithelial cells gathered from surgical samples from skin, cervix, esophagus and throat. Unlike cancer cell lines, some of which have been grown in laboratories around the world for years, these primary cells were minimally cultured.

To make these normal cells cancerous, the researchers used viruses to tweak just two genetic pathways known to be involved in uncontrolled growth. One drives cells forward in the cell cycle while the other disables an internal checkpoint that normally blocks abnormal proliferation. Many naturally occurring human cancers display identical genetic changes, and the researchers found that simultaneously altering the two pathways is highly effective at transforming normal cells.

Khavari and Ridky then added the altered, pre-cancerous epithelial cells to a tissue culture dish containing other components of human skin. Epithelial cells normally sit on a thin partition called the basement membrane that separates them from a lower layer of skin called the stroma. They found that at first the cells nestled down on the basement membrane and formed what looked like a normal, three-dimensional cross-section of skin. But within about six days, the cells started to behave more ominously punching through the membrane and invading the stromal tissue below.

"This reflects what we see happening in spontaneous human tumors," said Khavari. "Cells go from a pre-malignant state to invasive cancers, often over the course of years. Only in this intact, human-tissue model it occurs much more quickly." In contrast, unaltered cells remained obediently on their side of the basement membrane.

When the researchers examined the patterns of gene expression in the newly cancerous cells, they found that the patterns closely matched the genetic profiles of spontaneously occurring human cancers. But when the cells were grown in a single layer, without the basement membrane, stroma and normal three-dimensional tissue structure, their gene expression profiles were markedly different.

"This tells us that conclusions drawn from studying cells grown in two-dimensional culture need to be correlated with other findings to help ensure clinical relevance," said Khavari.

The researchers took advantage of their new "tumor-in-a-dish" model to test 20 new experimental anti-cancer drugs. Many of these drugs cannot be easily tested in animals because they are difficult to administer and may be toxic in their current form. But Khavari and Ridky were able to quickly home in on three promising candidates that stopped the altered epithelial cells from invading through the membrane. While the drugs will still have to be optimized for testing in animals, this type of pre-screening allows researchers to narrow down the possibilities.

The three-dimensional culture system also indicated that the stromal cells themselves somehow encourage the invasion of the altered epithelial cells, and that the cells don't need to be dividing wildly in order to be able to invade.

"These things had never been directly tested before in human tissue," said Khavari, who pointed out that the new model still doesn't incorporate many other biological players, such as the immune system and an active metabolism. And yet "now that we can create human tumors from multiple different human tissues, we have a new way to assess what might be going on in spontaneous human tumors."


'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Related medicine news :

1. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
2. Need a study break to refresh? Maybe not, say Stanford researchers
3. Stanford-led study disproves link between genetic variant, risk of coronary artery disease
4. Wider statin use could be cost-effective preventive measure, Stanford study finds
5. Preventive care poses dilemma for emergency departments, Stanford study finds
6. New treatment for severe aortic stenosis shown to save lives, Stanford researchers say
7. Arsenic shows promise as cancer treatment, Stanford study finds
8. Stanford Who's Who & Anthony Casimano Make Donation to Help Support National Organization, CancerCare
9. Melanoma-initiating cell identified by Stanford scientists
10. Pro Ana Versus Pro Recovery Sites: New Study by Johns Hopkins and Stanford University raises concerns.
11. Orphaned elderly serious casualty of African AIDS epidemic, Stanford study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology: